Ingenuity Blog
Your Molecule Has Met Its Match
Filter by:
Featured
Biomanufacturing Trends Shaping 2026
2026 is shaping up to be a year of steady progress for biopharmaceutical innovators. While development activity remains strong, sponsors are operating in a challenging environment characterized by increasingly complex modalities, lean resourcing, regulatory uncertainty, and heightened emphasis...
2026 is shaping up to be a year of steady progress for biopharmaceutical innovators. While development activity remains strong, sponsors...
Honoring its Oklahoma roots and global reach, Cytovance reflects on two decades of growth, innovation, and partnership as a trusted...
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, current microbial and...
Cytovance Biologics launches in-house formulation development, expanding end-to-end CDMO services for biotech and pharma customers.
While biopharma at large faces unprecedented pressure to innovate quickly and stay competitive, small biotech organizations are particularly impacted by...
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, current microbial and...
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, current microbial and...
New year, new programs! Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available...
This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide...
Cytovance recently appeared on the Outsourced Pharma Large Molecule Capacity Update to share how our available capacity, US-based manufacturing, and...
The Clinical Translation from Bench to BedsideBringing new and innovative therapeutics to patients is a fundamental purpose of translational science....
Like most industries, the ever-evolving biopharmaceutical landscape often experiences its ebbs and flows, with emerging biotechnology companies feeling the direst...
End of content
No more pages to load